http://orcid.org/0000-0002-7113-2372
References
- Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 2016;31:2619–31.
- Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 2012;61:2369–74.
- Escobar-Morreale HF, Roldàn-Martìn MB. Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. Diabetes Care 2016;39:639–48.
- Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014;20:8351–63.
- Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex Hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 2013;78:321–9.
- Le TN, Nestler JE, Strauss JF III, Wickam EP III. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 2012;23:32–40.
- Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
- Malin S, Kirwan JP, Sia CL, Gonzàles F. Pancreatic β-cell dysfunction in polycystic ovary syndrome: role of hyperglycemia-induced nuclear factor-κB activation and systemic inflammation. Am J Physiol Endocrinol Metab 2015;308:E770–7.
- Yuan X, Hu T, Zhao H, et al. Brown adipose tissue transplantation ameliorates polycystic ovary syndrome. Proc Natl Acad Sci USA 2016;113:2708–13.
- Calogero AE, Calabrò V, Catanuso M, et al. Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects. Endocrinol Invest 2011;34:630–44.